One should be aware that tumors classified in the past as GBM may carry an IDH1/IDH2 mutation or exhibit a G-CIMP phenotype (with or without an IDH1/IDH2 mutation), both of which are prognostic factors for longer survival in glioma patients [54]. The gene discussed is IDH2; the disease is central nervous system cancer.